Genmab invests heavily in artificial intelligence

”We believe that AI and access to more information digitally can help us in all parts of our business,” says Jan van de Winkel, CEO of Genmab.
Photo: Tuala Hjarnø / Genmab / Pr
Photo: Tuala Hjarnø / Genmab / Pr
By MarketWire

Artificial Intelligence, AI, is very much on the radar at Genmab, which is investing heavily in the new possibilities in the expectation that it will, among other things, shorten the path to market for new drugs.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading